Dow jumps 300 points to close above 44,000 for the first time as Trump enthusiasm continues
Bank stocks largely boosted the Dow, as investors hope the sector could see weaker regulation in a second Trump ...
Medpage Today on MSN9h
Higher BP Linked to Faster Visual Field Progression in Glaucoma
Higher mean blood pressure (BP) levels were associated with faster rates of visual field progression in patients with ...
AbbVie stock drops 12% on schizophrenia drug setback: should you buy the dip?
AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...
Crain's Chicago Business4d
AbbVie tumbles after new schizophrenia drug fails trials
AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...
Aldeyra's FDA Resubmission And AbbVie Option Revitalize Reproxalap's Prospects
Aldeyra received an FDA CRL for reproxalap, necessitating an additional study for DED approval. Read why I continue to rate ...
Positive Outlook on AbbVie: Geoff Meacham’s Buy Rating and Potential of Emraclidine Amid Schizophrenia Trial Challenges
AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Geoff Meacham ...
AbbVie Buy Rating Affirmed Despite Emraclidine Setback, Driven by Skyrizi and Rinvoq Growth
Terence Flynn, an analyst from Morgan Stanley, reiterated the Buy rating on AbbVie (ABBV – Research Report). The associated price target ...
WGN Radio4d
Wintrust Business Minute: AbbVie shares drop after disappointing drug trials
Steve Grzanich has the business news of the day with the Wintrust Business Minute. Shares of AbbVie have dropped sharply ...
FierceBiotech4d
AbbVie's $9B schizophrenia prospect flunks phase 2 trials, handing advantage to BMS
The drug candidate at the center of AbbVie’s $8.7 billion acquisition of Cerevel Therapeutics has failed a pair of phase 2 trials, dealing a blow to the program and a boost to rival Bristol ...